Natco Pharma Launches Affordable Generic Semaglutide Injection for Type 2 Diabetes in India

Natco Pharma Limited has announced the launch of its generic version of Semaglutide injection in the Indian market following the expiry of the patent. 

The company received approval from the Central Drugs Standard Control Organisation in February 2026 to manufacture and market the drug. The medication is used for the treatment of adults with insufficiently controlled type 2 diabetes mellitus and is prescribed along with diet and exercise.

Product Launch and Dosage Options

Natco plans to introduce the Semaglutide injection in multi-dose vial format under the brand names Semanat and Semafull. The product will be available in strengths of 2mg/1.5ml, 4mg/3ml and 8mg/3ml. The monthly price for the 2mg/1.5ml and 4mg/3ml variants has been set at ₹1,290, while the 8mg/3ml strength will be priced at ₹1,750.

In addition to the vial format, Natco also plans to launch a pen device version of the drug in April 2026. The pen devices will be priced at ₹4,000, ₹4,200 and ₹4,500 per month depending on the strength.

Affordable Alternative for Patients

Natco has become the first company to offer generic Semaglutide in a multi-dose vial format along with customised syringes. The company also intends to provide the product to third parties for co-marketing, which may further expand its reach in the Indian market.

The company highlighted that the vial-based formulation is significantly more affordable than existing options. The multi-dose vials are about 70% cheaper than pen devices and nearly 90% cheaper compared to the innovator’s brand.

Natco Pharma Share Price Today

On March 20, 2026, Natco Pharma share price opened at ₹950.00, touching the day’s high at ₹972.50, as of 11:03 AM on the NSE.

Also Read: NATCO Pharma to Consider Demerger of Agrochemical Business in Board Meet on March 24!

Conclusion

The launch of generic Semaglutide by Natco Pharma is expected to improve accessibility to GLP-1 therapy for diabetes patients in India. By offering a more affordable treatment option, the company aims to support better long-term treatment adherence and expand access to advanced diabetes care.

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a private recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.